Skip to main content
Premium Trial:

Request an Annual Quote

3D Signatures, Quebec Heart and Lung Institute Partner on Lung Cancer Study

NEW YORK (GenomeWeb) – Personalized medicine company 3D Signatures announced today that it has partnered with the Quebec Heart and Lung Institute (IUCPQ) to evaluate the clinical use of the company's TeloView software with DNA sequence analysis in lung cancer patients.

TeloView is designed to analyze the organization of telomeres, centromeres, and other structures in the nucleus in order to identify signals of specific cancers that can be used to inform treatment regimens.

Under the terms of the collaboration, IUCPQ will perform whole-exome sequence analysis on patients with non-small cell lung cancer, as well as provide matching tissue samples from its tumor bank. The study will be run by 3D Signatures at its Toronto-based lab in partnership with IUCPQ researcher Philippe Joubert.

Additional terms were not disclosed.

"This … is an exciting opportunity to evaluate how three-dimensional telomere analysis may complement other new tools at our disposal to offer potential benefits to healthcare providers, lung cancer patients, and the healthcare system," Joubert said in a statement.

"We hope this pilot study will be an important precedent for demonstrating how our TeloView platform may integrate with genomic sequencing with the aim of supporting clinical decisions for the precision care of such a large patient population as lung cancer," 3D Signatures CEO Jason Flowerday added.

Earlier this year, 3D Signatures released data showing that TeloView was able to distinguish Hodgkin's lymphoma patients that respond to standard chemotherapy from those who relapse or are refractory to treatment within one year.